Green Biologics Limited Overview
Green Biologics Limited was an Oxfordshire-based industrial biotechnology company that set out to revive acetone-butanol-ethanol (ABE) fermentation — a Clostridium-based process that had been displaced by petrochemical routes by the 1960s — using genetically improved solventogenic Clostridium strains and modern process engineering. Its thesis was that bio-based n-butanol and acetone could command premiums over petroleum equivalents in coatings, personal care, cleaning and consumer products, and that idle first-generation US corn-ethanol plants could be retrofitted cheaply to produce them. Backed by Sofinnova Partners, Swire Pacific, Capricorn, Oxford Capital and Morningside, it acquired and converted the 21-million-gallon Central Minnesota Ethanol Co-op plant, shipping commercially from late 2016 under the BioPure brand. Unable to reach cash break-even against petrochemical pricing, it closed the plant in July 2019. The UK parent pivoted to recombinant protein expression as Biocleave, before the legacy entity was struck off in December 2025.
What the company did
Across its 23-year legal life the entity passed through four distinct business models:
-
Integrated renewable chemicals producer (2014–2019). Through Green Biologics, Inc. and Central MN Renewables LLC, the group owned and operated a retrofitted corn-ethanol plant in Little Falls, Minnesota, producing bio-based n-butanol and acetone and marketing them, plus derivatives, into specialty chemicals and consumer-product supply chains.
-
Specialty biologics / protein expression (2019–2023, as Biocleave Limited). After the US closure, the UK parent changed its name to Biocleave and redeployed its CRISPR-based CLEAVE™ genome-editing toolkit to engineer Clostridium as a Gram-positive, endotoxin-free host for recombinant protein expression, supplying research reagents and contract expression services.
-
Non-trading shell (Aug 2023 – Dec 2025). After reverting to the Green Biologics name, the entity was classified as non-trading, moved its registered office to Wargrave, filed small-company accounts and was voluntarily struck off. The Biocleave operating business is understood to continue under BCL2020 Ltd (trading as biocleave).
Company's own description
The company described its Clostridium fermentation platform as converting a wide range of sustainable feedstocks into high-performance green chemicals — n-butanol, acetone and, via chemical synthesis, their derivatives — sold to a growing global customer base (2015 financing announcement). Its later tagline described renewable chemicals naturally designed to deliver performance that adds value to everyday products. No annual-report "business description" from a listed-company filing exists. In its Biocleave phase, the CEO described the business as still using solventogenic clostridia but applying CLEAVE™ genome editing to generate recombinant strains making higher-value products at much lower volumes (Microbiology Society interview, Oct 2020).
Revenue model
| Revenue stream | Era | Nature | Disclosure |
|---|---|---|---|
| Bulk/specialty chemical sales (n-butanol, acetone) | 2016–2019 | Product sales, B2B, domestic and export | Amounts not publicly disclosed |
| Derivative products (bio-IPA, butyl/isopropyl esters) | 2016–2019 | Product sales, partly via partner synthesis | — |
| Formulated consumer-product ingredients (nail polish remover acetone, lighter fluid, dry-cleaning solvent) | 2018–2019 | Ingredient supply into partner brands / private label | — |
| Fuel ethanol | Dec 2014 – c.2016 | Commodity product sales while the Little Falls plant continued to run as an ethanol plant pre-conversion | — |
| Technology licensing / R&D services | 2003–2014 and Biocleave era | Licensing, grants, collaborative R&D | — |
| Recombinant protein reagents and expression services | 2020–2023 (entity); continuing in successor | Catalogue products via distributors plus contract services | Not publicly disclosed; Preqin reports USD 0 revenue for 2022 at entity level |
Value-chain position and customers
In its operating peak, GBL sat at the midstream conversion stage: it bought US corn (the Little Falls plant historically consumed about 7.5 million bushels a year as an ethanol plant), fermented it to solvents, and sold molecules to formulators and brand owners. Customer types included coatings and adhesives manufacturers, personal-care contract formulators (Marianna Industries), retailers (Sally Beauty, via private label), consumer brands (Kingsford Charcoal) and specialty chemical firms (Kreussler for dry cleaning). End-markets cited for n-butanol at the time of the plant purchase were paints, coatings, adhesives, inks, plastics, pharmaceuticals, food ingredients, household cleaners and personal care.
Independent characterisation
Green Biologics is best understood as a capital-intensive industrial-biotech scale-up that failed on unit economics, not on technology. The company proved the process at commercial scale (commercial shipments from December 2016; USDA BioPreferred certification; Kosher and Halal certification; launch of several "world's first" bio-based consumer products) but could not close the cost gap with petrochemical acetone and oxo-butanol, which are low-cost by-products or high-scale products of integrated petrochemical chains. Its premium-niche strategy (consumer products where "bio-based" carries a price premium) generated launches but evidently not enough volume to fill a 21-million-gallon-equivalent plant before investors withdrew support in mid-2019. The Biocleave pivot was a classic "salvage the IP" strategy: re-deploy strain-engineering know-how into low-volume, high-value biologics.
Strategy
Historic strategic themes (operating era)
Retrofit, not greenfield: Management argued that converting a first-generation ethanol plant demonstrated a low-capex path to renewable chemicals; CMEC's CEO called the deal pioneering proof that such retrofits were possible (Brainerd Dispatch, Dec 2014).
Chemicals over fuels: The thesis, articulated at the 2013 plant deal, was that n-butanol as a chemical was worth more than double ethanol as a fuel, targeting buyers such as coatings and adhesives makers.
Premium "bio-based" positioning: USDA BioPreferred, Kosher/Halal certification, American Chemistry Council membership and Responsible Care alignment were used to differentiate from petrochemical commodities.
Downstream partnerships: Consumer launches with Kingsford, Kreussler and Marianna/Sally Beauty sought to capture brand premiums and build demand pull.
Biocleave strategy (2019–2023)
Redeploy CLEAVE™ strain engineering to make high-value, low-volume products — recombinant proteins, toxins and research reagents — exploiting Clostridium's Gram-positive, endotoxin-free profile and its tolerance of proteins toxic to E. coli. Commercial infrastructure included distributor agreements and standard terms (Harper James), academic placements (South Coast Biosciences DTP) and a KTP with Aston University on membrane-associated proteins.
Last 24 months (Oct 2024 – Oct 2026)
For the profiled legal entity, the only "initiative" in the last 24 months was its orderly closure: final accounts (Jul 2025), strike-off application (Sep 2025) and dissolution (Dec 2025). No medium-term financial targets, ESG commitments or cost programmes were published. Any current strategy belongs to the successor BCL2020 Ltd and is not publicly disclosed in sources reviewed.
Products & Services
Renewable chemicals (2016–2019)
| Product | Description | Key specs/capabilities | Target customer | Launch | Pricing |
|---|---|---|---|---|---|
| BioPure n-butanol | 100% bio-based normal butanol from Clostridium fermentation of US corn | USDA Certified Biobased / BioPreferred; Kosher & Halal certified; drop-in replacement for petro n-butanol | Coatings, adhesives, inks, plastics, pharma, food ingredients, cleaners, personal care | Commercial shipments Dec 2016 | Not disclosed; positioned at premium to petro grade |
| BioPure acetone | 100% bio-based acetone, co-product of ABE fermentation | USDA BioPreferred; differentiated impurity profile cited by management as a performance benefit | Personal care (nail care), cleaning, solvents | Dec 2016 | — |
| Bio-based isopropyl alcohol (IPA) | High-purity 100% bio-based IPA (via derivatisation of acetone) | Listed in portfolio via own manufacturing and partner collaborations | Personal care, cleaning, pharma | c.2016–2017 | — |
| Specialty esters | Esters of n-butanol, isopropanol and other bio-based alcohols | Partner-manufactured; solvent and fragrance applications | Coatings, flavours & fragrances, cleaning | c.2016–2017 | — |
| Fuel ethanol | Produced at Little Falls (21 MMgy nameplate) pre-conversion | Commodity | Fuel blenders | Dec 2014 – 2016 | Market price |
Formulated / co-branded consumer applications (2018–2019)
| Product | Partner | Description | Launch | Notes |
|---|---|---|---|---|
| Bio-based acetone nail polish remover ("Beauty Secrets") | Marianna Industries (formulator, Omaha, NE); Sally Beauty (retailer) | Billed as the world's first plant-derived acetone nail polish remover; 100% USDA BioPreferred | 25 Jun 2018 | Carried in over 3,000 Sally Beauty stores; offered for further private-label/branded deals |
| EcoLight natural charcoal lighter fluid | Kingsford Charcoal | Bio-based lighter fluid using GBL solvents | Jan–Mar 2018 | Consumer retail via Kingsford |
| Bio-based dry-cleaning solvent | Kreussler (Florida-based) | Corn-based dry-cleaning solvent | Announced Apr 2018 | Production collaboration |
Technology platform
| Platform | Description | Status |
|---|---|---|
| Solventogenic Clostridium strains | Proprietary improved strains producing acetone and n-butanol from sugars | Proven at commercial scale 2016–2019 |
| Advanced fermentation / retrofit process | Process to retrofit first-generation dry-mill ethanol plants to ABE production | Deployed at Little Falls |
| CLEAVE™ | Patented CRISPR-based genome-editing technology for Clostridium enabling stable SNPs, insertions and deletions | Carried into Biocleave |
Biocleave-era offerings (2020–2023 at entity; continuing in successor)
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Clostridium recombinant protein expression service | Gram-positive host lacking lipopolysaccharide; endotoxin levels reported below 0.005 EU per µg | Life-science researchers, therapeutics, agritech, flavour & fragrance | Contract service model |
| Catalogue reagents | Bacterial toxins and toxin fragments (safely expressed in Clostridium), protozoal, clostridial and cancer-research proteins including PARPs | Academic and pharma research | Sold directly and via distributors (agreements drafted with Harper James) |
| Membrane-associated protein expression | Capability under development via Knowledge Transfer Partnership with Aston University | Pharma research | Run through BCL2020 Ltd |
Financial Narrative
Data availability
The entity filed group accounts for FY2019 and FY2020, and small-company "total exemption full" accounts for FY2021–FY2025. Fiscal years end 30 June.
Income statement
Note: dividends are shown as zero on the basis that a loss-making venture-funded company with accumulated deficits cannot lawfully distribute under UK company law; no dividend has ever been reported. The Preqin EBITDA figure (USD -33,282) and Craft EBIT (GBP -25.0K) are broadly consistent once currency conversion is considered (c.GBP 25K ≈ USD 31–33K at 2022 rates). Margins and revenue CAGR are not computable.
Share capital (from statutory filings)
The FY2019 column reflects the statement of capital at 9 Nov 2018 (second-filed SH06) and the FY2020 column the statement at 26 Sep 2019; both relate to share cancellations around the investor exit and recapitalisation. A senior convertible loan was approved by resolution dated 26 Aug 2019.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not publicly disclosed and cannot be computed from the verified data.
Historical capital raised (operating era)
Commentary. The financial story is one of heavy, front-loaded capital consumption (over USD 100M from late 2013 to 2015 alone) to acquire and retrofit a commodity-scale plant, followed by a revenue ramp that never reached break-even. The capitalisation table shows the 2018 investor-director exits (Sofinnova, Capricorn, Oxford Capital in October–November 2018, Swire in January 2019) foreshadowing the July 2019 withdrawal of financial support. Post-2019 the legal entity became financially immaterial: by FY2022 it reported essentially nil revenue, a c.GBP 25K loss and c.GBP 51K cash, consistent with a holding/shell role while operations migrated to the successor. The FY2023–FY2025 total-exemption accounts and the 2025 strike-off application confirm the entity had no material assets or liabilities at the end (a DS01 can only be filed by a company that has not traded in the prior three months and has no outstanding creditor issues it is aware of).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Role | Status |
|---|---|---|---|
Green Biologics Limited (04358718) | England & Wales | Group parent; UK R&D labs (Milton Park, Abingdon); strain development | Renamed Biocleave 2019; reverted name 2023; dissolved 16 Dec 2025 |
Green Biologics, Inc. | USA (Ohio-based) | US operating company; sales & marketing (Medina, OH); earlier Gahanna/Columbus, OH | — |
Central MN Renewables LLC | USA (Minnesota) | Owner/operator of Little Falls plant; held rolled-over CMEC member equity/debt | — |
BCL2020 Ltd (trading as "biocleave") | England & Wales (presumed) | Successor protein-expression business | Active per Aston University KTP documentation; relationship to 04358718 inferred, not confirmed by filings reviewed |
Segment Revenue
| Segment (analytical) | FY2017 | FY2018 | FY2019 |
|---|---|---|---|
Segment (analytical) | FY2021 | FY2022 | FY2023 |
Protein expression / Biocleave revenue at entity level (USD Mn) | — | 0 | — |
Income Statement and Income Statement (USD)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (USD, Preqin) | — | 0 | — | — | — |
Operating income / EBIT (GBP Mn, Craft) | — | -0.025 | — | — | — |
EBITDA (USD, Preqin) | — | -33,282 | — | — | — |
Net income (GBP Mn, Craft) | — | -0.025 | — | — | — |
Dividends per share (GBP) | 0 | 0 | 0 | 0 | 0 |
Key Financials
| Metric | FY2022 |
|---|---|
Cash and equivalents (GBP Mn, Craft) | 0.051 |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (GBP Mn) | 0 | 0 | 0 | 0 | 0 |
Key Financials (GBP)
| Metric | FY2019 | FY2020 |
|---|---|---|
Issued share capital nominal value after cancellations (GBP) | 15,239.90 | 13,871.06 |
Round Details
| Round | Date | Amount | Lead / participants | Source |
|---|---|---|---|---|
Seed rounds | Pre-2010 | c.GBP 0.37M combined | Not specified | Unquote |
Series A-type | May 2010 | GBP 4.9M | Oxford Capital Partners, Capricorn Venture Partners, Carbon Trust, Morningside | Unquote |
Series B | Dec 2013 | USD 25M (GBP 15.4M) | Sofinnova Partners, Swire Pacific (board seats from Nov 2013) | Unquote; Business Magazine |
Follow-on equity | 2015 | USD 42M | Co-led by Swire Pacific and Sofinnova; Capricorn, Oxford Capital, Morningside, ConvergInce Holdings participated | Business Magazine |
Debt and rollover | 2015 | USD 34M | Predominantly Tennenbaum Capital Partners debt; plus CMEC members' rolled equity/debt in Central MN Renewables | Business Magazine |
Total (aggregator) | 2003–2019 | USD 139.5M | — | Crunchbase via StartupBlink |
Biocleave-era (aggregator) | 2019–2023 | USD 2.69M | Not specified | PitchBook |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable — never listed |
Dividend history | None paid |
Buyback authorisations | None; share cancellations in 2018–2019 relate to restructuring |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed; 2015 Tennenbaum debt and 2019 senior convertible loan known to have existed |
Balance Sheet
| Metric | FY2014 | FY2016 |
|---|---|---|
Equity raised (USD Mn) | 25 | 42 |
Debt and rolled-over funding raised (USD Mn) | — | 34 |
Analyst Conclusions
Management guidance / consensus. None. The profiled entity is dissolved; there is no guidance, consensus or forward outlook. The relevant forward-looking question concerns the successor (BCL2020 Ltd, trading as biocleave), for which no financial disclosures were located.
Bull-case arguments (for the technology/successor)
-
Proven platform: the team took ABE fermentation to commercial scale in 2016 and holds patented CLEAVE™ editing — a rare depth of Clostridium know-how.
-
Differentiated expression niche: sub-0.005 EU/µg endotoxin and toxin tolerance create a defensible technical niche against E. coli-based suppliers.
-
Capital-light model: reagents and services require far less capital than the 21 MMgy plant that sank the original business.
Bear-case arguments
-
Entity extinct: Green Biologics Limited was dissolved on 16 Dec 2025; there is no investable or contractable entity under this name.
-
Track record of cash burn: over USD 100M raised without reaching break-even; the 2019 closure crystallised investor losses.
-
Micro-scale successor: USD 0 entity revenue in 2022, c.14 employees in 2023, and the CEO's own identification of fundraising as a major challenge point to fragility.
Catalysts and monitorables (next 12 months)
-
Any Companies House restoration application for 04358718 (possible within six years of dissolution if assets or claims emerge).
-
BCL2020 Ltd filings (accounts, charges, funding rounds) and product/distribution announcements under the biocleave brand.
-
Licensing or sale of legacy Green Biologics/CLEAVE™ patents.
-
Activity in UK bio-ABE and Clostridium peers (e.g., Celtic Renewables, CHAIN Biotechnology) that might seek legacy IP.
Analyst verdict
Green Biologics Limited should be removed from any "public company" coverage list: it was never listed and, as of 16 December 2025, no longer exists as a legal entity. Its history is nonetheless instructive as a case study in industrial-biotech commercialisation. Technically, the company succeeded where many peers did not. It modernised a century-old Clostridium fermentation, retrofitted a working Minnesota ethanol plant, achieved commercial shipments by December 2016, secured federal bio-based certifications, and placed bio-acetone into a mass retail channel through Sally Beauty's 3,000-plus stores. Commercially, it failed on the one variable that matters most in commodity chemicals: cost. Oxo-butanol and phenol-co-product acetone are made in integrated, depreciated, world-scale complexes; a single corn-based fermentation plant could not match them, and the consumer premium niches GBL cultivated were too small to absorb a 21-million-gallon-equivalent asset's output. The sequential exit of every venture director between October 2018 and January 2019 was the leading indicator; the July 2019 announcement that funding could not be secured was the inevitable outcome.
The 2019–2023 Biocleave pivot was rational — redeploying genome-editing IP into low-volume, high-value recombinant proteins where Clostridium's endotoxin-free profile is an advantage — but the legal entity itself became a shell with nil revenue and minimal cash, and the operating business appears to have moved to BCL2020 Ltd before the old company was renamed back and struck off. For counterparties, the practical implications are: any contracts, IP assignments or claims must be traced to the successor or, for dissolved-company assets, to the Crown (bona vacantia) unless restored. For investors, there is no exposure to price. For strategists, the lesson is that drop-in bio-chemicals need either structural cost parity or locked-in offtake at a premium before committing to commodity-scale capacity. Overall verdict: entity dissolved — not investable; monitor successor only.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Birth (month/year) | Background |
|---|---|---|---|---|
Sean George Cronin Sutcliffe | Director; long-time CEO of Green Biologics | 29 Apr 2008 | Dec 1963 | Led the company through its financing, US acquisition and commercialisation phases (CEO per Unquote, 2015) |
Dr Elizabeth Rachael (Liz) Jenkinson | Director; CEO of Biocleave | 26 Sep 2019 | May 1980 | Joined GBL as a bench scientist and rose to CTO responsible for UK R&D labs; became Chief Executive on the 2019 pivot (Microbiology Society) |
Karen Elizabeth Stanley | Director | 26 Sep 2019 | May 1967 | Background not publicly detailed in sources reviewed |
Executive Leadership Team
| Name | Affiliation (where evident) | Appointed | Resigned |
|---|---|---|---|
Dr Edward McConachie Green | Founder; later founder/CEO of CHAIN Biotechnology (2014) | 25 Jan 2003 | 29 Nov 2013 |
Dr Edward Timothy Davies | Early director (US-resident) | 11 Oct 2003 | 13 Dec 2010 |
Simon Jones | Director | 1 May 2005 | 10 Apr 2006 |
Dr Andrew George Rickman | Director/chair-level investor (role not specified) | 30 Aug 2006 | 29 Nov 2013 |
Dr Victor Christou | Director (two terms) | 27 Sep 2007 / 15 Dec 2010 | 11 May 2009 / 19 Sep 2012 |
Gerald Chan | Morningside | 4 Feb 2009 | 16 Jun 2010 |
Dr Simon Turner | Director | 22 Apr 2009 | 15 Dec 2010 |
Dr John Richard Marsh | Oxford Capital address | 20 May 2009 | 18 Mar 2010 |
David John Brister | Oxford Capital Partners | 1 Jun 2010 | 1 Nov 2018 |
Claude Stoufs | Capricorn Venture Partners | 1 Jun 2010 | 10 Oct 2018 |
Reenie (Irene) McCarthy | Morningside address | 16 Jun 2010 | 29 Nov 2013 |
Thomas James Grote | Chief Financial Officer | 1 Jan 2012 | 15 Jul 2015 |
Joel Arthur Stone | President, Green Biologics Inc. | 1 Jan 2012 | 29 Nov 2013 |
Simon Iliff Mansfield | Director | 20 Mar 2013 | 12 Jul 2017 |
Denis Jacques Lucquin | Sofinnova Partners | 29 Nov 2013 | 10 Oct 2018 |
Philippe Paul Lacamp | Swire Pacific (One Pacific Place address) | 29 Nov 2013 | 15 Jul 2015 |
James Joseph Hohman | Director (US) | 1 Feb 2015 | 20 Jun 2019 |
Man Ching Maggie Leung | Swire Pacific | 15 Jul 2015 | 1 Jan 2019 |
Mark Noel Witt | Director (Houston, TX) | 15 Jul 2015 | 14 Jul 2016 |
Martin Incledon Blair | Director | 1 Jan 2018 | 20 Jun 2019 |
Brad Pritchard | Director (US) | 10 Oct 2018 | 26 Sep 2019 |
Keon Alexander Reed | Director (US) | 10 Oct 2018 | 26 Sep 2019 |
John Bruce Rae-Smith | Director | 1 Nov 2018 | 26 Sep 2019 |
Martin Cubbon | Director (Isle of Man) | 1 Nov 2018 | 26 Sep 2019 |
Paul Robert Henson | Director | 1 Jan 2019 | 26 Sep 2019 |
Tamsin Denise Crane | Director | 26 Sep 2019 | 14 Dec 2020 |
Executive Leadership Team — David Anderson
| Name | Title | Source |
|---|---|---|
David Anderson | Global Vice President of Marketing | Sofinnova/Happi press releases, 2016–2018 |
Joel Stone | President, Green Biologics Inc. (2013) | St. Cloud Times |
Dr Liz Jenkinson | Chief Technology Officer (pre-2019) | Microbiology Society |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Type | Positioning vs GBL |
|---|---|---|---|
Petro n-butanol (oxo) | BASF | Integrated petrochemical major | Massive scale, low-cost oxo process; price-setter |
Petro n-butanol (oxo) | Dow | Integrated major | Scale and integration advantage |
Petro n-butanol (oxo) | OQ Chemicals (formerly Oxea) | Oxo specialist | Cost leadership in oxo alcohols |
Petro n-butanol/acetone | Eastman Chemical | Specialty/integrated | Broad solvent portfolio |
Petro acetone (cumene/phenol co-product) | INEOS Phenol | Phenol/acetone leader | By-product economics make acetone structurally cheap |
Bio-butanol / isobutanol | Gevo | Listed renewable fuels/chemicals developer | Also retrofitted a Minnesota ethanol plant (Luverne); pivoted to fuels |
Bio-butanol | Butamax (BP/DuPont JV) | Corporate JV | Isobutanol fuel focus; IP disputes with Gevo |
Bio-ABE | Celtic Renewables (Scotland) | Private | ABE from whisky by-products; closest UK peer |
Bio-butanol | Cobalt Technologies | Private (historic) | Earlier US bio-butanol developer |
Clostridium technology | CHAIN Biotechnology | Private (founded by GBL founder) | Clostridium for healthcare products |
Protein expression (Biocleave) | Thermo Fisher, GenScript, Lonza and E. coli/yeast CROs | Large tools/CRO players | Scale and breadth; Biocleave differentiates on endotoxin-free, toxin-tolerant host |



